Home » Newsletters » BioWorld

BioWorld

Jan. 26, 2000

View Archived Issues

Other News To Note

British Biotech Faces Setback Following Marimastat Study

Mystery of Maternal Tolerance Found In Embryonic Protein That Checks Complement Onslaught

Maxim Registers For Offering Expected To Bring In $100M

Synaptic, Kissei Collaborate To Identify Novel Receptors

Xoma Getting $35M In License Deal With Baxter For Neuprex

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.